Sverige - svensk - Läkemedelsverket (Medical Products Agency)

norbrook laboratories limited - enrofloxacin - injektionsvätska, lösning - 100 mg/ml - bensylalkohol hjälpämne; enrofloxacin 100 mg aktiv substans - enrofloxacin - nöt

USA - engelsk - NLM (National Library of Medicine)

professional compounding centers of america dba pcca - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin usp for veterinary use only *protect from light* for prescription compounding/rx only part: 30-4815 gm cas: 93106-60-6 danger: harmful substance. irritating substance. may cause eye, skin or respiratory irritation. possible hypersensitization. avoid raising and breathing dust use adequate ventilation. avoid alkalies. emits toxic fumes under fire conditions. wash thoroughly after handling. store in tightly closed container. preserve in well-closed,light resistant container. store at room temperature.

Israel - engelsk - Ministry of Health

a.l. medi-market ltd. - enrofloxacin - solution for injection - enrofloxacin 50 mg / 1 ml - in calves:treatment of infections of the respiratory tract caused by enrofloxacin susceptible strains of pasteurella multocida, mannheimia haemolytica and mycoplasma spp. treatment of infections of the alimentary tract caused by enrofloxacin susceptible strains of escherichia coli. treatment of septicaemia caused by enrofloxacin susceptible strains of escherichia coli. treatment of acute mycoplasma-associated arthritis due to enrofloxacin susceptible strains of mycoplasma bovis.only after the sensitivity of the bacteria has been proven and it has been found that there is no alternative treatment (proven resistance to other agents).

USA - engelsk - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - baytril® (brand of enrofloxacin) antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. baytril antibacterial tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

USA - engelsk - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - baytril® (brand of enrofloxacin)taste tabs® antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. baytril antibacterial tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or gia

USA - engelsk - NLM (National Library of Medicine)

mwi/vetone - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

USA - engelsk - NLM (National Library of Medicine)

aspen veterinary resources®, ltd - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

USA - engelsk - NLM (National Library of Medicine)

api solutions - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) -

USA - engelsk - NLM (National Library of Medicine)

letco medical, llc - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) -

USA - engelsk - NLM (National Library of Medicine)

letco medical, llc - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) -